Biovitrum Full Year Report 2006.Strong Profit Improvement from Operations During 2006 STOCKHOLM, Sweden -- January - December * Net revenues for the year increased by 28 percent to SEK SEK In currencies, this is the abbreviation for the Swedish Krona. Notes: The currency market, also known as the Foreign Exchange market, is the largest financial market in the world, with a daily average volume of over US $1 trillion. 1,201.1 M (936.6) * Operating profit Operating profit (or loss) Revenue from a firm's regular activities less costs and expenses and before income deductions. operating profit See operating income. excluding capital gain from divestment of property, restructuring costs and non recurring costs related to the stock exchange listing amounted to SEK 128.6 (-20.6) * Net profit for the year amounted to SEK 92.7 M (176.2) and earnings per share before dilution to SEK 2.0 (3.4) * Cash and cash equivalents and short-term investments amounted to SEK 903.9 M (1,621.3) on December 31 * Biovitrum was listed on the Stockholm Stock Exchange The Stockholm Stock Exchange (Swedish: Stockholmsbörsen) is a stock exchange located in Stockholm, Sweden. Founded in 1863 [1] it is the primary securities exchange of the Nordic Countries. on September 15 * Phase I study initiated within the 5-HT6 project for the treatment of obesity * Phase IIa study initiated within the 5-HT2A project for the treatment of glaucoma glaucoma (glôkō`mə), ocular disorder characterized by pressure within the eyeball caused by an excessive amount of aqueous humor (the fluid substance filling the eyeball). * Partnership agreements signed with biotech companies Symphogen, Syntonix and Synphora to develop new drug projects * Aloxi[R] launched in the Nordic market * October - December * Net revenues for the fourth quarter fell by 34 percent to SEK 244.8 M (369.3) * The loss for the quarter amounted to SEK -6.3 M (230.2) and the earnings per share before dilution to SEK -0.1 (4.4) "Biovitrum's (SRTO SRTO Sender Retransmission Time-Out : BVT BVT Bouvet Island (ISO Country code) BVT Brevet BVT Bournville Village Trust (UK) BVT Build Verification Test (Software testing process) ) stock exchange listing in September was, of course, the most important event in 2006," says Mats Pettersson, CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. of Biovitrum. "During the year the strong trend was sustained as our revenues and project portfolio continued to grow. We made great strides in all areas of our business and have a strong platform to continue developing Biovitrum successfully in 2007" For more information, see www.biovitrum.com. About Biovitrum Biovitrum is one of the largest biopharma companies in Europe. With operations in Sweden and in the UK, Biovitrum conducts research and develops pharmaceuticals for unmet medical needs both common diseases and conditions that affect smaller patient populations. Biovitrum focuses on drugs for the treatment of obesity, diabetes, inflammation and blood diseases, as well as a number of well-defined niche indications. Biovitrum develops and produces protein-based drugs on a contractual basis and markets a range of specialist pharmaceuticals primarily in the Nordic countries. This information was brought to you by Waymaker http://www.waymaker.net |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion